Status:

COMPLETED

Treatment Study for Actinic Cheilitis Comparing Imiquimod 5% and Photodynamic Therapy

Lead Sponsor:

Norwegian University of Science and Technology

Collaborating Sponsors:

St. Olavs Hospital

Conditions:

Actinic Cheilitis

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Actinic cheilitis is a common precancerous lesion of the lip. The purpose of this study is to compare imiquimod 5% therapy and photodynamic therapy. The data will include effect data, histology (skin ...

Detailed Description

Randomized study comparing imiquimod 5% with photodynamic therapy for actinic cheilitis. Histological, efficacy, epidemiological and clinical data will be collected.

Eligibility Criteria

Inclusion

  • Clinical findings of actinic cheilitis.
  • Histological findings demonstrating epithelial changes equal to or greater than mild epithelial dysplasia in severity (mild - moderate - severe).
  • Age above 18.
  • Willingness to take post-treatment biopsy.

Exclusion

  • Disorders predisposing to photosensitivity (porphyria, SLE).
  • Pregnancy or nursing.
  • Known allergy to any excipients in the study creams.
  • prescribed topical retinoids, 5-fluorouracil, cryodestruction, surgical excision and curettage.

Key Trial Info

Start Date :

March 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2013

Estimated Enrollment :

53 Patients enrolled

Trial Details

Trial ID

NCT00849992

Start Date

March 1 2009

End Date

November 1 2013

Last Update

May 15 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

St. Olavs Hospital

Trondheim, Norway, 7006